NASDAQ:GBT
Global Blood Therapeutics, Inc.
- Stock
Last Close
68.48
04/10 20:00
Volume Today
3.28M
Avg: -
PE Ratio
−27.41
PFCF: -
Dec '13 | Dec '14 | Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | ||
|---|---|---|---|---|---|---|---|---|---|---|
average inventory | 638.50K - | 20.75M 3,149.80% | 49.21M 137.17% | |||||||
average payables | 693K - | 1.95M 181.53% | 3.84M 96.85% | 5.75M 49.68% | 6.61M 15.01% | 8.33M 26.05% | 14.85M 78.19% | 17.09M 15.07% | ||
average receivables | 1.32M - | 10.07M 663.63% | 23.15M 129.93% | |||||||
book value per share | -1.19 - | -3.58 200.82% | 10.99 406.73% | 5.61 48.97% | 7.53 34.26% | 11.20 48.67% | 9.92 11.39% | 6.79 31.62% | 3.12 54.00% | |
capex per share | -0.04 - | -0.02 45.57% | -0.08 230.36% | -0.04 47.49% | -0.07 79.96% | -0.09 28.72% | -0.06 37.09% | -0.14 140.58% | -0.05 64.00% | |
capex to depreciation | -1.76 - | -0.48 72.45% | -1.14 134.53% | -1.09 3.76% | -1.87 70.85% | -1.05 44.01% | -0.35 66.73% | -0.81 132.18% | -0.38 53.61% | |
capex to operating cash flow | 0.06 - | 0.02 74.90% | 0.03 100.25% | 0.02 37.90% | 0.03 66.98% | 0.04 6.89% | 0.02 50.06% | 0.04 132.17% | 0.01 69.53% | |
capex to revenue | -1.64 - | -0.07 95.69% | -0.02 76.52% | |||||||
cash per share | 0.15 - | 3.78 2,416.17% | 11.60 206.47% | 4.43 61.75% | 7.44 67.72% | 9.34 25.51% | 10.46 12.03% | 9.14 12.56% | 10.88 18.99% | |
days of inventory on hand | 9.71K - | 7.39K 23.87% | 6.41K 13.34% | |||||||
days payables outstanding | 80.76K - | 3.51K 95.66% | 1.66K 52.61% | |||||||
days sales outstanding | 456.60 - | 51.59 88.70% | 53.98 4.62% | |||||||
debt to assets | 5.21 - | 1.88 63.81% | 0.08 95.74% | 0.08 0.97% | 0.11 33.80% | 0.07 31.69% | 0.27 276.13% | 0.43 55.70% | 0.79 86.00% | |
debt to equity | -1.24 - | -2.13 72.13% | 0.09 104.09% | 0.09 1.05% | 0.12 37.82% | 0.08 34.17% | 0.38 379.86% | 0.74 96.90% | 3.78 411.25% | |
dividend yield | ||||||||||
earnings yield | -0.02 - | -0.04 81.94% | -0.11 219.26% | -0.17 53.49% | -0.07 59.12% | -0.08 18.06% | -0.06 30.64% | -0.09 61.95% | -0.16 76.58% | |
enterprise value | 936.50M - | 541.20M 42.21% | 265.54M 50.94% | 387.77M 46.03% | 1.47B 278.34% | 1.82B 24.35% | 4.41B 141.68% | 2.32B 47.49% | 1.82B 21.53% | |
enterprise value over ebitda | -53.26 - | -26.87 49.55% | -5.84 78.27% | -4.77 18.23% | -12.72 166.40% | -10.76 15.41% | -17.17 59.58% | -10.20 40.57% | -6.52 36.07% | |
ev to operating cash flow | -63.71 - | -26.90 57.78% | -8.60 68.04% | -5.73 33.39% | -15.77 175.44% | -13.48 14.55% | -22.68 68.29% | -10.93 51.81% | -7.07 35.27% | |
ev to sales | 2.09K - | 18.70 99.11% | 9.33 50.12% | |||||||
free cash flow per share | -0.72 - | -1.49 107.06% | -2.49 67.58% | -2.08 16.45% | -2.27 9.18% | -2.74 20.68% | -3.39 23.79% | -3.60 6.02% | -4.13 14.89% | |
free cash flow yield | -0.02 - | -0.03 107.06% | -0.08 123.46% | -0.14 86.94% | -0.06 59.91% | -0.07 15.69% | -0.04 36.07% | -0.08 94.58% | -0.14 70.00% | |
graham net net | -1.32 - | -3.85 190.89% | 10.64 376.13% | 3.95 62.86% | 6.54 65.60% | 8.46 29.29% | 6.78 19.90% | 4.67 31.11% | -0.12 102.51% | |
graham number | 4.72 - | 11.04 133.94% | 29.92 171.00% | 17.71 40.83% | 21.65 22.26% | 29.29 35.32% | 31.96 9.09% | 24.82 22.32% | 18.39 25.91% | |
income quality | 0.81 - | 0.97 19.17% | 0.67 31.10% | 0.82 23.25% | 0.79 3.20% | 0.78 2.23% | 0.73 6.22% | 0.86 17.43% | 0.85 0.99% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -24.79 - | -18.60 24.97% | ||||||||
interest debt per share | 1.29 - | 2.67 106.07% | 10.73 302.55% | |||||||
inventory turnover | 0.04 - | 0.05 31.36% | 0.06 15.39% | |||||||
invested capital | 0.13 - | 0.37 183.28% | 3.36 809.60% | |||||||
market cap | 939.78M - | 593.27M 36.87% | 414.04M 30.21% | 479.85M 15.89% | 1.67B 247.08% | 2.10B 26.08% | 4.64B 120.79% | 2.66B 42.70% | 1.84B 30.66% | |
net current asset value | -28.42M - | -51.49M 81.17% | 138.54M 369.07% | 133.69M 3.50% | 286.40M 114.22% | 440.94M 53.96% | 410.59M 6.88% | 324.32M 21.01% | 59.17M 81.75% | |
net debt to ebitda | 0.19 - | 2.59 1,286.62% | 3.26 26.28% | 1.13 65.28% | 1.72 51.68% | 1.62 5.55% | 0.88 45.61% | 1.50 70.22% | 0.09 94.01% | |
net income per share | -0.83 - | -1.51 81.94% | -3.62 139.43% | -2.48 31.40% | -2.76 11.34% | -3.41 23.17% | -4.57 34.31% | -4.04 11.76% | -4.82 19.34% | |
operating cash flow per share | -0.67 - | -1.46 116.82% | -2.41 64.97% | -2.04 15.45% | -2.20 7.77% | -2.65 20.42% | -3.33 25.96% | -3.45 3.62% | -4.08 18.15% | |
payables turnover | 0.00 - | 0.10 2,203.41% | 0.22 111.00% | |||||||
receivables turnover | 0.80 - | 7.07 784.98% | 6.76 4.42% | |||||||
research and ddevelopement to revenue | 82.81 - | 1.25 98.49% | 1.09 13.06% | |||||||
return on tangible assets | -2.94 - | -0.37 87.29% | -0.30 18.84% | -0.41 34.54% | -0.33 19.49% | -0.28 14.03% | -0.34 18.81% | -0.34 2.04% | -0.32 5.62% | |
revenue per share | 0.04 - | 2.02 5,484.55% | 3.09 53.33% | |||||||
roe | 0.70 - | 0.42 39.52% | -0.33 178.06% | -0.44 34.43% | -0.37 17.07% | -0.30 17.15% | -0.46 51.58% | -0.59 29.04% | -1.54 159.42% | |
roic | 12.74 - | 0.42 96.71% | 0.31 24.87% | -5.97 1,995.54% | 2.53 142.39% | -3.00 218.61% | -1.55 48.23% | 0.85 154.98% | 0.65 24.27% | |
sales general and administrative to revenue | 55.54 - | |||||||||
shareholders equity per share | -1.19 - | -3.58 200.82% | 10.99 406.73% | 5.61 48.97% | 7.53 34.26% | 11.20 48.67% | 9.92 11.39% | 6.79 31.62% | 3.12 54.00% | |
stock based compensation to revenue | 21.66 - | 0.58 97.33% | 0.40 30.03% | |||||||
tangible asset value | -25.97M - | -49.33M 89.91% | 140.79M 385.44% | 186.31M 32.33% | 318.80M 71.12% | 572.80M 79.67% | 578.69M 1.03% | 416.16M 28.09% | 196.41M 52.80% | |
tangible book value per share | -1.19 - | -3.58 200.82% | 10.99 406.73% | 5.61 48.97% | 7.53 34.26% | 11.20 48.67% | 9.92 11.39% | 6.79 31.62% | 3.12 54.00% | |
working capital | -35K - | 51.06M 145,974.29% | 140.10M 174.40% | 134.25M 4.17% | 298.05M 122.00% | 452.01M 51.66% | 556.54M 23.13% | 553.13M 0.61% | 713.97M 29.08% |
All numbers in USD (except ratios and percentages)